Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $201.8 million.

  • Editas Medicine's Liabilities and Shareholders Equity fell 3840.92% to $201.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 3839.86%. This contributed to the annual value of $341.6 million for FY2024, which is 3156.63% down from last year.
  • As of Q3 2025, Editas Medicine's Liabilities and Shareholders Equity stood at $201.8 million, which was down 3840.92% from $210.6 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Liabilities and Shareholders Equity registered a high of $780.3 million during Q1 2021, and its lowest value of $201.8 million during Q3 2025.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $504.6 million (2023), whereas its average is $492.6 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 6718.07% in 2021, then crashed by 4527.54% in 2025.
  • Editas Medicine's Liabilities and Shareholders Equity (Quarter) stood at $677.5 million in 2021, then fell by 24.08% to $514.3 million in 2022, then fell by 2.95% to $499.2 million in 2023, then tumbled by 31.57% to $341.6 million in 2024, then plummeted by 40.94% to $201.8 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $201.8 million for Q3 2025, versus $210.6 million for Q2 2025 and $263.7 million for Q1 2025.